Form 4: Novavax CFO Kelly's Equity Transactions

Novavax's EVP, CFO, and Treasurer, James Patrick Kelly, reported significant equity transactions including RSU vesting, tax-related share disposals, and new grants of RSUs and stock options.

Summary

• EVP, CFO, and Treasurer James Patrick Kelly reported changes in beneficial ownership of Novavax Inc. common stock and derivative securities.
• On March 1, 2026, 58,666 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 58,666 shares of common stock.
• Concurrently, 28,366 shares of common stock were disposed of at $10.14 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Kelly beneficially owned 101,963 shares of common stock directly.
• On March 2, 2026, Kelly was granted 129,500 new Restricted Stock Units (RSUs) with a vesting schedule of one-third on each of the first three anniversaries of the grant date.
• Also on March 2, 2026, Kelly was granted 194,000 non-statutory stock options with an exercise price of $9.09. These options vest one-quarter on the first anniversary and the remainder monthly over the subsequent three years.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive compensation and retention efforts through equity grants, which can align management's interests with long-term shareholder value. The transactions are routine for an insider filing.

Positives

• Grant of 129,500 new Restricted Stock Units (RSUs) to a key executive, aligning management incentives with shareholder value.
• Grant of 194,000 non-statutory stock options with an exercise price of $9.09, providing further incentive for long-term performance.

Negatives

• Disposal of 28,366 shares of common stock at $10.14 per share to cover tax withholding, which is a standard practice but reduces direct ownership.

Risks

• Vesting of RSUs and stock options is subject to continued employment, posing a retention risk if the executive departs.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $9.09.

Future Outlook

The grants of new Restricted Stock Units and non-statutory stock options indicate a long-term incentive structure for the EVP, CFO, and Treasurer, aligning future compensation with the company's stock performance and continued employment through the vesting periods extending to 2029 and 2030 respectively.

Management Comments

• No direct management quotes are provided in this Form 4 filing, which is typical for this document type.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like the CFO are a standard practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and retention. The vesting schedules, tied to continued employment over several years, reflect a common strategy to ensure executive commitment to the company's strategic goals and shareholder value creation. The specific terms of these grants, including the number of units and options, would typically be benchmarked against peer companies to ensure competitive compensation.

Comparison to Industry Standards

• This Form 4 filing details standard executive compensation practices within the biotechnology sector. For example, similar RSU and stock option grants with multi-year vesting schedules are common at companies like Moderna (MRNA) and BioNTech (BNTX) for their senior leadership, aiming to align executive interests with long-term shareholder value.
• The specific grant sizes for Novavax's CFO would be evaluated against the company's market capitalization, performance, and peer group compensation data, such as those reported by companies like Pfizer (PFE) or Johnson & Johnson (JNJ) for their executive teams, though the scale would differ significantly given company size.
• The tax withholding for RSU vesting is also a universal practice across industries.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with long-term shareholder value creation, potentially incentivizing performance. The tax-related share disposal is a minor, routine event.
• Employees: The grants demonstrate the company's use of equity compensation to retain key talent, which could be viewed positively by other employees regarding their own potential compensation structures.

Next Steps

• Continued vesting of 129,500 RSUs on the first three anniversaries of March 2, 2026, subject to continued employment.
• Continued vesting of 194,000 non-statutory stock options, with 1/4 vesting on the first anniversary of March 2, 2026, and the remainder monthly over the following three years, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, including RSU vesting and new equity grants. While these grants align executive incentives with long-term company performance, they do not provide new fundamental information about Novavax's operational or financial outlook that would warrant a change in investment recommendation. The transactions are standard for an insider and do not suggest a significant shift in company prospects or insider sentiment.

Keywords

Novavax, NVAX, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, CFO, James Patrick Kelly